Biobanking Containment Drugs 
pharmaphorum
JULY 28, 2022
The finding came from an analysis of sequencing data from more than 360,000 individuals in the UK Biobank , which contains genetic and health information from half a million UK participants. The post Alnylam finds belly fat gene and drug target in UK Biobank study appeared first on.
XTalks
FEBRUARY 4, 2021
The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Generation of strong research dataset cohorts must begin with high-quality clinical samples.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 4, 2020
The test has also been validated in CENTOGENE’s CAP / CLIA / ISO certified analytical laboratory and has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for use by authorized laboratories. Important Notice and Disclaimer. Securities and Exchange Commission (SEC).
The Pharma Data
NOVEMBER 11, 2020
MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE. Multiple new and extended drug discovery and development agreements. Access to QUOD biobank to expand patient database into liver disease. m (9M 2019: € 321.4 m (9M 2019: € 308.1
XTalks
APRIL 15, 2021
Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. However, these drugs have shown limited effectiveness in treating HFpEF. Case Study: Genomic Approaches in Coronary Artery Disease Drug Development.
The Pharma Data
JULY 8, 2021
Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. PFIZER DISCLOSURE NOTICE: The information contained in this release is as of July 8, 2021. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Biogen Safe Harbor.
XTalks
SEPTEMBER 16, 2022
In fact, one in every 600,000 cells in the lungs of a 50-year-old already contains potentially cancerous mutations. This means that a drug like an IL-1? And although EGFR and KRAS mutations are commonly found in lung cancer not caused by smoking, they alone are not enough to trigger the cancer. The Double Hit.
Expert insights. Personalized for you.
52 
Let's personalize your content